Free Content

Lessons from genetic profiling in soft tissue sarcomas

Authors: Nilbert, M.1; Meza-Zepeda, L. A.2; Francis, P.1; Berner, J. M.2; Namløs, H. M.1; Fernebro, J.1; Myklebost, O.2

Source: Acta Orthopaedica Scandinavica, Volume 75, Supplement 311, Supplement 311/April 2004 , pp. 35-50(16)

Publisher: Informa Healthcare

Buy & download fulltext article:

Free content The full text is free.

View now:
PDF 2,366.7kb 


Soft tissue sarcomas represent a heterogeneous group of tumors and include over 50 histotypes. Some of these tumor types are characterized by specific chromosomal translocations, whereas other types show complex genetic aberrations. The recent developments within gene expression technologies have now been applied to studies of soft tissue sarcomas (STS) and the first results indicate that genetic signatures are useful for classification and diagnosis. Distinctive expression profiles have been found in e.g. gastrointestinal stromal tumors (GISTs), synovial sarcomas, malignant peripheral nerve sheath tumors (MPNSTs), and in subsets of liposarcomas. The more pleomorphic tumor types, such as high-grade variants of leiomyosarcomas, malignant fibrous histiocytomas (MFHs), fibrosarcomas, and subtypes of liposarcomas, show a greater variability among the expression profiles, but interestingly subsets with distinctive expression profiles can be identified also among these tumors. The data available place many of the genes hypothesized to be involved in the development of a certain type of STS, such as the KIT gene in GIST development, among the top discriminating genes. Thereby expression profiling provides novel insights into the pathogenesis of STS. Although much work remains to be done to validate the data and to define optimal discriminating gene lists, the current lessons from gene expression studies in STS are encouraging and imply that genetic signatures may serve as diagnostic and prognostic markers and may help identify novel therapeutic strategies.

Document Type: Research Article


Affiliations: 1: Dept of Oncology, University Hospital, Lund, Sweden 2: Dept of Tumour Biology, the Norwegian Radium Hospital, Oslo, Norway

Publication date: April 1, 2004

More about this publication?
Related content


Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page